Anduril Hires Rocket Lab to Help It With Hypersonics

Rocket Lab secured an additional $30 million partnership with Anduril to support three HASTE hypersonic launches, on top of its earlier $190 million Pentagon HASTE contract. The new work could add nearly 5% to annual revenue and reinforces HASTE as roughly one-third of Rocket Lab's contracted backlog. The article frames the news as supportive for revenue diversification and backlog growth, though the article is largely commentary rather than a new operational update.

Analysis

The incremental signal here is not the dollar amount; it is validation that hypersonic test capacity is becoming a reusable product, not a bespoke government one-off. Once a platform proves it can iterate quickly with high reliability, the bottleneck shifts from launch physics to program orchestration, data capture, and range access — all of which favors the incumbent with flight cadence and integrated hardware/software control. That creates a flywheel where each successful mission lowers customer hesitation and raises the probability of follow-on private and government demand.

The second-order winner is likely Rocket Lab’s launch infrastructure and subsystems stack, not just the test-flight revenue line. A defense customer paying for near-term experimentation effectively subsidizes utilization of a fixed-cost asset base, which should improve gross margin leverage and keep Electron economically relevant longer than the market may have assumed. The hidden risk for competitors is that “defense-adjacent” credibility becomes a gating criterion for future hypersonic and responsive-launch awards, making the market more winner-take-most even before Neutron is operational.

From a timing standpoint, this is a months-to-years catalyst, but the near-term tape reaction can overshoot because investors will extrapolate backlog quality into terminal economics. The main reversal risk is schedule slippage or a pause in hypersonic procurement if budget scrutiny rises; this would hit sentiment faster than revenue because the equity is still trading on narrative momentum. Another underappreciated risk is customer concentration inside a small number of defense programs — good for near-term visibility, but it can amplify volatility if any one program changes scope.

The contrarian angle is that the market may be underpricing the durability of the legacy vehicle. If Electron remains a cash-generating launch-and-test workhorse longer, the path to Neutron is less binary and capital intensity is spread over a larger revenue base. That supports a higher quality multiple, but only if management avoids the trap of overinvesting in growth before utilization proves out.

Key Decisions for Investors

• Long RKLB on pullbacks over the next 1-3 weeks; thesis is that defense-test repeatability extends the useful life of Electron and supports margin durability. Target a 3-6 month horizon with upside tied to additional HASTE-style contract awards; trim if valuation expands faster than backlog grows.
• Buy RKLB Jan-2027 call spreads to express the Neutron + defense-flywheel thesis with defined risk. Prefer medium-dated structures because the fundamental re-rating is a 2-4 quarter story, not a single-news-event trade.
• Pair trade: long RKLB / short unprofitable launch peers with less defense exposure over 3-6 months. The edge is in revenue quality and cadence; exit if competitors show equivalent hypersonics traction or if Rocket Lab execution slips.
• If already long RKLB, sell near-dated covered calls into strength. The stock can remain structurally supported, but the market is likely to overreact to backlog headlines before proving sustained cash conversion.